Key result
Revised ACC/AHA and HFSA guidelines for chronic heart failure emphasize neurohormonal blockade with ACE inhibitors and beta-blockers, and expand the role of aldosterone antagonists and ARBs.
Population
Patients with chronic heart failure (CHF)
Design
Review
Authors
Loading...
May aid pharmacists applying revised HF guidelines; leaves open real-world impact on adherence and outcomes.
This review summarizes key drug therapy recommendations from the revised ACC/AHA and HFSA guidelines for chronic heart failure to aid pharmacists in their implementation.
Michael A. Crouch (2006) conducted a review in chronic heart failure (CHF). Pharmacotherapy for chronic heart failure was evaluated. Revised ACC/AHA and HFSA guidelines for chronic heart failure emphasize neurohormonal blockade with ACE inhibitors and beta-blockers, and expand the role of aldosterone antagonists and ARBs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: